image credit: Unsplash

Revvity, AstraZeneca Enter Next-Gen Gene Editing Platform Pact

May 18, 2023

Revvity, a provider of health sciences services, entered a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile.

The Pin-point system and the underlying base editing technology is designed to enable highly efficient and precise single and multiplex (multi-gene) editing without unintended impact on cell viability or functionality. Compared to traditional CRISPR technologies, which create double-stranded breaks in the DNA, this newer editing system uses a modified Cas enzyme that only nicks one strand of the DNA. This allows for a more controlled approach to gene disruption and base correction.

Read More on Contract Pharma